LSI is Officially Heading to Singapore — Register for LSI Asia '25 Today

Mnemosyne Pharmaceuticals

First-in-class subunit-selective NMDA receptor modulators to treat neuropsychiatric diseases, specifically schizophrenia and Alzheimer\'s.

Get a Demo and See the Full Profile

Get a demo today to see profiles of Mnemosyne Pharmaceuticals plus 6116 other startups.

Learn More About Mnemosyne Pharmaceuticals

Technology/product details

Revenue projections

Capital raised to date

Growth strategy

Competing Startups

More